Stereotaxis to Establish Global Headquarters in Downtown St. Louis Globe Building
08 Março 2021 - 11:00AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, today
announced it will move its global headquarters to the Globe
Building in downtown St. Louis at the end of this year.
“Establishing our new headquarters at the Globe
is another exciting step in our effort to modernize every aspect of
Stereotaxis and build a foundation to support years of significant
growth,” says David Fischel, Stereotaxis Chairman and CEO. “Our new
space is being designed to support improved collaboration across an
expanding team along with a three-fold expansion of our surgical
robot manufacturing capacity.”
Referred to as “The Hi-Tech Castle,” the Globe
Building is located in downtown St. Louis’ Innovation District. The
building is home to a range of technology companies where robust
connectivity infrastructure and cybersecurity is required.
Stereotaxis’ neighbors in the downtown tech corridor will include
merchant services tech giant, Square, who announced their move
downtown in 2019, T-Rex, the technology incubator serving more than
200 startups and organizations, as well as the new National
Geospatial-Intelligence Agency (NGA) West campus.
“We are delighted to partner with and support
Stereotaxis in their vision to advance healthcare with robotics,
technology, and connectivity,” says Steve Stone, owner of the Globe
Building. “We look forward to welcoming them into our community and
having them contribute to the revitalization of downtown St.
Louis.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute “forward-looking” statements, usually containing the
words “believe,” “estimate,” “project,” “expect” or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Stereotaxis (AMEX:STXS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024